PHP
APLS

Parkman Healthcare Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Parkman Healthcare Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,000
Closed -$1.65M – 96
2023
Q1 		$1.65M Buy
+25,000
New +$1.44M 0.36% 63

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parkman Healthcare Partners's APLS Position: Q2 2023 in Review

Parkman Healthcare Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2023, closing a stake of 25,000 shares — an estimated $1.65M sold.

Parkman Healthcare Partners first reported a position in APLS in Q1 2023 and held it in 1 quarter. The position peaked at $1.65M in Q1 2023. 317 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

  • Parkman Healthcare Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 25,000 Apellis Pharmaceuticals shares in Q2 2023, an estimated $1.65M.
  • Parkman Healthcare Partners first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Parkman Healthcare Partners's Apellis Pharmaceuticals position peaked at $1.65M in Q1 2023.
  • 317 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on Parkman Healthcare Partners's 13F filing for Q2 2023, filed 11 Aug 2023.